Microba Life Sciences Limited (MAP.AX)
AUD 0.19
(0.0%)
AUD 0.19
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 58.04 Million AUD | 23.61% |
| 2023 | 46.95 Million AUD | 18.93% |
| 2022 | 39.47 Million AUD | 113.54% |
| 2021 | 18.48 Million AUD | 71.06% |
| 2020 | 10.8 Million AUD | -22.75% |
| 2019 | 13.99 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 65.23 Million AUD | 65.24% |
| 2024 Q4 | 58.04 Million AUD | 0.0% |
| 2024 Q2 | 65.23 Million AUD | 0.0% |
| 2024 FY | 58.04 Million AUD | 23.61% |
| 2023 Q3 | 46.95 Million AUD | -9.08% |
| 2023 FY | 46.95 Million AUD | 18.93% |
| 2023 Q4 | 39.47 Million AUD | -15.92% |
| 2023 Q2 | 51.64 Million AUD | 0.0% |
| 2023 Q1 | 51.64 Million AUD | 30.8% |
| 2022 FY | 39.47 Million AUD | 113.54% |
| 2022 Q4 | 39.47 Million AUD | 0.0% |
| 2022 Q3 | 39.47 Million AUD | 144.25% |
| 2022 Q2 | 16.16 Million AUD | 0.0% |
| 2022 Q1 | 16.16 Million AUD | -12.57% |
| 2021 Q3 | 18.48 Million AUD | 0.0% |
| 2021 FY | 18.48 Million AUD | 71.06% |
| 2021 Q1 | - AUD | 0.0% |
| 2021 Q4 | 18.48 Million AUD | 0.0% |
| 2020 FY | 10.8 Million AUD | -22.75% |
| 2019 FY | 13.99 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Australian Clinical Labs Limited | 593.06 Million AUD | 90.213% |
| BCAL Diagnostics Limited | 12.26 Million AUD | -373.196% |
| Genetic Signatures Limited | 67.28 Million AUD | 13.742% |
| Genetic Technologies Limited | 6.18 Million AUD | -838.174% |
| Healius Limited | 2.98 Billion AUD | 98.054% |
| Imagion Biosystems Limited | 4.58 Million AUD | -1165.523% |
| Integral Diagnostics Limited | 744.27 Million AUD | 92.202% |
| INOVIQ Ltd | 21.7 Million AUD | -167.397% |
| Monash IVF Group Limited | 508.47 Million AUD | 88.585% |
| Rhythm Biosciences Limited | 1.51 Million AUD | -3721.69% |
| Sonic Healthcare Limited | 14.82 Billion AUD | 99.609% |